top of page

Latest News

Sep 30, 2024

Delphian Tx is awarded $2.9M Phase 2 SBIR from U.S. National Institutes of Health to advance to First in Human trials.

The $2.9M follows grant from the National Institute on Drug Abuse enables Delphian to use its Seed Financing toward a phase 1 clinical trial.

Read More
Delphian Tx is awarded $2.9M Phase 2 SBIR from U.S. National Institutes of Health to advance to First in Human trials.

May 1, 2024

Delphian Tx Closes $2.7M Seed Round to advance development of S1-221 for migraine

Delphian Tx has secured $2.7M in seed funding to advance its lead candidate, S1-221, an optimized combination of CBD:THC to treat migraine, into phase 1 clinical trials in 2025. 

Read More
Delphian Tx Closes $2.7M Seed Round to advance development of S1-221 for migraine
bottom of page